Northwestern Mutual Wealth Management Co. purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 839,483 shares of the medical equipment provider’s stock, valued at approximately $35,829,000.
Other institutional investors have also added to or reduced their stakes in the company. Renaissance Group LLC bought a new position in Boston Scientific during the fourth quarter valued at about $28,064,000. Perigon Wealth Management LLC bought a new stake in shares of Boston Scientific in the second quarter valued at $883,000. Y Intercept Hong Kong Ltd lifted its position in shares of Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after buying an additional 670,060 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in shares of Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after acquiring an additional 28,961 shares during the period. Finally, Meiji Yasuda America Inc bought a new position in shares of Boston Scientific during the 4th quarter worth $4,708,000. 89.07% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 194,522 shares of company stock valued at $9,385,210 over the last quarter. 0.34% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on Boston Scientific
Boston Scientific Trading Up 2.1%
NYSE BSX opened at $50.39 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock’s 50-day simple moving average is $46.34 and its two-hundred day simple moving average is $57.86. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a market capitalization of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.
Boston Scientific announced that its board has initiated a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its stock is undervalued.
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Stories
- Five stocks we like better than Boston Scientific
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
